| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
Upstream Bio, Inc.$7.53
-0.28 (-3.59%)
C 42Pipeline Score Overvalued Biotech · Clinical
Market Cap
455.50 M
EPS
-2.90
P/E Ratio
-
Value Trade
5.07 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
1.03 M
R&D Expenses
36.56 M
Operating CF
-47.85 M
Total Assets
318.05 M
Total Liabilities
14.06 M
Equity
304.00 M
D/E Ratio
12,345
-2.56 %
Week
-10.1 %
1 Month
-0.48 %
3 Month
-66.13 %
6 Month
-61.07 %
5 Year
-61.07 %
All Time
Cash Data
Cash Position
294.58 M
Monthly Burn
15.95 M
Runway
16.8 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
341.67 K
52 Week Range
7.25 - 33.68
% held by Insiders
33.43 %
% held by Institutions
65.98 %
Enterprise Value
162.03 M
Total Shares
54.38 M
Short %
12.69 %
Float Shares
32.36 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Upstream Bio, Inc.
68Total events
5Upcoming
14Tier-1 (high impact)
2024 – 2027Coverage
Upcoming catalysts 5
TBD
T2FDA Feedback Received
Planned regulatory interactions to discuss VIBRANT data for potential approval submissions
TBD
T3Poster Presentation
Additional details from VALIANT to be presented at future medical conference
TBD
T3Poster Presentation
Plans to present further details from VIBRANT at an upcoming medical conference
Event history 63
Jun 14, 2026
▲Oral PresentationVerekitugPresentation
New responder analyses from Phase 2 VIBRANT trial presented at EAACI 2026
Chronic rhinosinusitis with nasal polyps (CRSwNP)source ↗
Jun 14, 2026
◆Oral PresentationVerekitugPresentation
Additional efficacy data from Phase 2 VIBRANT trial of verekitug in CRSwNP presented at EAACI 2026
chronic rhinosinusitis with nasal polypssource ↗
May 18, 2026
▲Poster PresentationVerekitugPresentation
Poster presentation at ATS 2026 showing ACQ-6 improvement and biomarker data
chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthmasource ↗
May 13, 2026
●Enrollment MilestoneVerekitugTrial
Enrollment capped in VENTURE trial; over 400 participants enrolled
COPDsource ↗
Q2 2026
Mar 1, 2026
◆Late-BreakerVerekitugPresentation
Late-breaking poster presentation of additional analyses from Phase 2 VIBRANT trial at AAAAI 2026
chronic rhinosinusitis with nasal polypssource ↗
Mar 1, 2026
▲Late-BreakerVerekitugPresentation
Late-breaking poster presentation of additional analyses from Phase 2 VIBRANT trial at AAAAI 2026
chronic rhinosinusitis with nasal polypssource ↗
Mar 1, 2026
▲Primary Endpoint MetVerekitugClinical Data
Primary endpoint met: endoscopic nasal polyp score reduction -1.95 (WOCF) and -1.77 (primary analysis) at week 24
chronic rhinosinusitis with nasal polypssource ↗
Mar 2026
▲Enrollment CompleteVerekitugTrial
Enrollment completed in VALOUR long-term extension study
severe asthmasource ↗
Drug Pipeline Intelligence
C42
Pipeline Score $185M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.4x
rNPV / MCap Top 60%
Micro Cap (rank 365 of 911)
Percentile RankUpstream Bio, Inc. carries a moderate pipeline score (42/100), with $669M risk-adjusted pipeline value, led by Verekitug in Severe Asthma (Phase 2), across $80B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verekitug Small molecule | Chronic Obstructive Pulmonary Disease | Phase 2 | NCT06981078 | 14% | $479M | ACTIVE NOT_RECRUITING | 666 | VERY_FAST | B (73) | Jul 1, 2028 | LOW_RISK | MEDIUM Jun 10, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
verekitug | chronic rhinosinusitis with nasal polyps (CRSwNP) | Phase 2 | 2026-06-14 | primary endpoint result: 80%; placebo adjusted reduction: -1.95 (p<0.0001) Read More | Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Read More | |
verekitug | chronic rhinosinusitis with nasal polyps (CRSwNP) | Phase 2 | 2026-06-14 | primary endpoint result: 80%; placebo adjusted reduction: -1.95 (p<0.0001) Read More | Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Read More | |
verekitug | chronic rhinosinusitis with nasal polyps (CRSwNP) | Phase 2 | 2026-06-14 | primary endpoint result: 80%; placebo adjusted reduction: -1.95 (p<0.0001) Read More | Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in UPB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
UPB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
UPBUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
Upstream Bio presented new analyses from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at EAACI 2026. The results showed that around 80% of participants experienced clinically meaningful improvements in nasal polyp scores, with notable enhancements in secondary endpoints such as nasal congestion and total symptom scores. The findings support the potential of verekitug as a treatment option for patients inadequately controlled by standard therapies.
Read more →UPB▼ -8.5%on this news
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Upstream Bio will present additional efficacy data from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps at the EAACI 2026 Congress. The presentation will focus on a responder analysis showing clinically meaningful improvements in patients. Verekitug is a novel TSLP receptor antagonist, currently the only one in clinical development.
Read more →UPB▲ +5.2%on this newsshared move
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Upstream Bio, a clinical-stage biotechnology company, will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. CEO Rand Sutherland will participate in a fireside chat, which will be available via live webcast. The company is developing verekitug, a monoclonal antibody targeting TSLP for severe respiratory disorders.
Read more →UPB▼ -6.4%on this news
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
Upstream Bio presented new data from the Phase 2 VIBRANT trial at the ATS 2026 International Conference, highlighting the efficacy of verekitug in improving asthma controls for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The results demonstrated significant reductions in asthma symptoms and nasal polyp scores, along with improvements in inflammatory biomarkers. Approximately 60% of participants in the trial had comorbid asthma, and the treatment led to a marked decrease in reliance on systemic corticosteroids and surgeries. Upstream Bio plans to advance to Phase 3 trials for verekitug in both CRSwNP and severe asthma in early 2027.
Read more →UPBUpstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Upstream Bio reported its Q1 2026 financial results, highlighting advancements in its Phase 3 programs for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The company plans to meet with the FDA for End-of-Phase 2 discussions in mid-2026 and expects to initiate Phase 3 trials in Q1 2027. Despite a net loss increase, Upstream Bio maintains a strong cash position to support ongoing operations.
Read more →UPBUpstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Upstream Bio, Inc. will present new data from its Phase 2 VIBRANT trial of verekitug at the ATS 2026 International Conference. The presentations will focus on the drug's effects in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. This trial evaluates verekitug's impact on nasal and blood biomarkers, showcasing its potential in treating inflammatory diseases.
Read more →UPBUpstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Upstream Bio has outlined a Phase 3 development strategy for verekitug, targeting severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The company reported positive results from its Phase 2 VALIANT trial, showing significant improvements in asthma exacerbations. With a strong cash position, Upstream plans to initiate Phase 3 trials in early 2027, focusing on high-dose quarterly administration.
Read more →UPBUpstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
Upstream Bio presented additional analyses from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps at the AAAAI 2026 Annual Meeting. The trial showed a significant reduction in nasal polyp scores and nasal congestion scores, supporting the drug's efficacy. The results also indicated a substantial decrease in the need for surgery or systemic corticosteroids. Upstream Bio is preparing to initiate Phase 3 trials for verekitug.
Read more →UPBUpstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
Upstream Bio will present new analyses from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps at the AAAAI Congress 2026. The presentation will focus on efficacy endpoints adjusted for concomitant rescue therapy use. This event underscores the company's commitment to addressing severe respiratory disorders.
Read more →UPBUpstream Bio to Participate in Upcoming March Investor Conferences
Upstream Bio, Inc. announced that CEO Rand Sutherland will participate in several investor conferences in March 2026. The company is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Their lead candidate, verekitug, is in Phase 2 trials for chronic rhinosinusitis, severe asthma, and COPD. Live webcasts of the presentations will be available on their website.
Read more →UPB▼ -47.2%on this news· ran to -70% by day 3
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
Upstream Bio announced positive results from the Phase 2 VALIANT trial of verekitug for severe asthma, demonstrating significant reductions in annualized exacerbation rates and improvements in lung function. The drug was well tolerated, and over 90% of participants have enrolled in a long-term extension study. Upstream Bio plans to advance verekitug into Phase 3 trials following regulatory interactions.
Read more →UPB▼ -47.2%on this news· ran to -70% by day 3shared move
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
Upstream Bio will host a webcast on February 11, 2026, to report top-line results from the Phase 2 VALIANT trial of verekitug, a treatment for severe asthma. The trial involved 478 patients and assessed the drug's safety and efficacy over a minimum of 24 weeks. Verekitug is the only known antagonist targeting the TSLP receptor currently in clinical development.
Read more →UPB▼ -47.2%on this news· ran to -70% by day 3shared move
This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be ide
Upstream Bio, Inc. presented promising results from the Phase 2 VALIANT trial, showing a significant reduction in asthma exacerbation rates with their investigational drug, verekitug. The trial achieved its primary endpoint, demonstrating both safety and efficacy with meaningful improvements in lung function. Despite these positive indicators, the company acknowledged the risks associated with further clinical development, regulatory approval processes, and the need for additional funding. The drug represents a significant advancement for severe asthma treatment, with plans for further studies underway.
Read more →UPBUpstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Upstream Bio, a clinical-stage biotechnology firm, announced that CEO Rand Sutherland will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company focuses on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Their lead product, verekitug, is in Phase 2 trials for several conditions, including chronic rhinosinusitis and severe asthma.
Read more →UPB▲ +10.7%on this news
Upstream Bio to Participate in Upcoming December Investor Conferences
Upstream Bio, Inc. has announced its participation in several investor conferences scheduled for December. CEO Rand Sutherland will represent the company, which is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company is advancing its monoclonal antibody, verekitug, into Phase 2 trials for various conditions, including chronic rhinosinusitis and severe asthma.
Read more →UPBUpstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
Upstream Bio reported positive results from the VIBRANT Phase 2 trial of verekitug for CRSwNP, demonstrating significant effects on key endpoints. The company is on track to release results from the VALIANT Phase 2 trial in severe asthma in early 2026. Financially, Upstream Bio holds $372.4 million in cash, though it reported a net loss of $33.7 million for Q3 2025, reflecting increased R&D expenses.
Read more →UPBUpstream Bio to Participate in Upcoming November Investor Conferences
Upstream Bio, a clinical-stage biotechnology company, announced that CEO Rand Sutherland will participate in investor conferences in November. The company focuses on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Their lead candidate, verekitug, is currently in Phase 2 trials for conditions like chronic rhinosinusitis and severe asthma.
Read more →UPB▲ +8.5%on this news
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
Upstream Bio presented data at the European Respiratory Society Congress highlighting verekitug's unique mechanism of action targeting the TSLP receptor. The findings suggest that verekitug effectively inhibits TSLP signaling, leading to significant clinical benefits in patients with chronic rhinosinusitis and potential applications in severe asthma and COPD. The company anticipates further data from ongoing trials in 2026.
Read more →UPBUpstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Upstream Bio, Inc. will have its CEO, Rand Sutherland, participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025. The company is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. They are advancing their monoclonal antibody, verekitug, into Phase 2 trials for various conditions.
Read more →UPB▲ +18.3%on this news
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Upstream Bio has reported positive top-line results from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP). The trial demonstrated significant reductions in nasal polyp and congestion scores, with a favorable safety profile and no serious adverse events. The results suggest that verekitug could enhance treatment standards for CRSwNP and may have implications for other respiratory diseases.
Read more →UPB▲ +18.3%on this newsshared move
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Upstream Bio, Inc. is set to report top-line data from the Phase 2 VIBRANT trial of verekitug, designed for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial, which is randomized and placebo-controlled, evaluates the efficacy and safety of verekitug administered every 12 weeks for 24 weeks. The results announcement is scheduled for September 2, 2025, and will be accompanied by a conference call and webcast. Verekitug is notable as the only clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), addressing significant healthcare needs in this domain.
Read more →UPB▲ +7.9%on this news
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
Upstream Bio reported its financial results for Q2 2025, highlighting progress in its clinical trials for verekitug, a monoclonal antibody targeting the TSLP receptor. The company completed enrollment in a Phase 2 trial for severe asthma and initiated trials for COPD. They expect to report top-line data from multiple trials in the coming months. Despite a significant net loss, the company has sufficient funds to continue operations until 2027.
Read more →UPBUpstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
Upstream Bio has initiated a Phase 2 clinical trial, VENTURE, for verekitug in patients with moderate-to-severe COPD. This trial aims to evaluate the drug's efficacy and safety, broadening its development into a third indication. The study will involve approximately 670 adults and assess various endpoints related to COPD exacerbations and lung function.
Read more →UPBTranslational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
Upstream Bio presented pharmacology modeling data at the EAACI Congress, highlighting verekitug's greater potency as a TSLP receptor antagonist compared to tezepelumab. This novel monoclonal antibody is being developed for severe respiratory diseases, including asthma and COPD. Upcoming Phase 2 clinical trial results are anticipated, which may further validate its efficacy.
Read more →UPBUpstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
Upstream Bio announced a presentation at the EAACI Congress 2025, focusing on verekitug's mechanism of action targeting the TSLP receptor. The data suggests that this approach may enhance potency compared to existing treatments. Verekitug is currently in multiple Phase 2 trials for severe asthma and chronic rhinosinusitis, with promising preclinical results.
Read more →UPBUpstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Upstream Bio, Inc. announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, where CEO Rand Sutherland will engage in a fireside chat on June 11, 2025. The company focuses on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Notably, Upstream Bio's lead candidate, verekitug, is in Phase 2 trials, targeting conditions such as severe asthma and chronic rhinosinusitis. The event provides a platform for the company to highlight its innovations in addressing unmet patient needs.
Read more →UPBUpstream Bio Appoints Stacy Price as Chief Technology Officer
Upstream Bio, Inc. has appointed Stacy Price as Chief Technology Officer, effective immediately. Price brings over 25 years of experience in technical operations and manufacturing within the biotechnology sector. In her new role, she will lead the expansion of technical operations and product development for verekitug, a treatment in clinical development for inflammatory diseases. The appointment comes at a critical time as Upstream Bio prepares to initiate a third clinical program for verekitug, enhancing the company's leadership team.
Read more →UPB▼ -5.4%on this news
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs – Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nas
Upstream Bio reported its first quarter 2025 financial results, highlighting its developments in the clinical programs for verekitug. The company anticipates top-line data from its Phase 2 trials targeting chronic rhinosinusitis with nasal polyps and severe asthma, with both readouts expected in the coming years. Upstream Bio maintains a strong financial position with $431.4 million in cash, which should support its operational goals through 2027. However, the company recorded a significant net loss this quarter, raising concerns about escalating expenses in research and development.
Read more →UPB▲ +7.8%on this news
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights – Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with na
Upstream Bio reported its Fourth Quarter and Full Year 2024 financial results, highlighting the completion of enrollment in the Phase 2 clinical trial for its drug, verekitug, targeting chronic rhinosinusitis with nasal polyps. The company successfully completed an upsized IPO, raising approximately $293 million, which will extend its financial runway through 2027. While the company noted a significant increase in net loss and research expenses, it remains optimistic about upcoming data releases and ongoing development for severe asthma and COPD treatments. Top-line data from the CRSwNP trial is expected in the second half of 2025.
Read more →UPB▼ -6%on this news
Upstream Bio to Present at Upcoming March Investor Conferences
Upstream Bio, Inc. (Nasdaq: UPB), focused on developing treatments for inflammatory diseases, will present at two upcoming investor conferences in March 2025. CEO Rand Sutherland will lead the presentations at the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Biopharma Conference. The company is advancing its monoclonal antibody, verekitug, through Phase 2 trials for severe asthma and chronic rhinosinusitis, along with plans for development in chronic obstructive pulmonary disease.
Read more →UPB▼ -7.5%on this news· ran to -25% by day 3
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Upstream Bio, Inc. (Nasdaq: UPB) announced that CEO Rand Sutherland will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The company specializes in developing treatments for inflammatory diseases, particularly severe respiratory disorders. Upstream Bio is advancing its monoclonal antibody, verekitug, into Phase 2 trials targeting severe asthma and chronic rhinosinusitis. The presentation aims to highlight the company's innovations and commitment to addressing unmet medical needs.
Read more →UPBUpstream Bio Appoints Allison Ambrose as General Counsel
Upstream Bio, a clinical-stage biotechnology company, announced the appointment of Allison Ambrose as General Counsel. With over 15 years of experience in the biotech sector, Ambrose will oversee the company's legal functions and join the executive leadership team. Her appointment comes at a time when Upstream is focusing on developing its lead drug candidate, verekitug, for severe respiratory disorders. The company aims to address substantial unmet medical needs as it progresses through clinical trials.
Read more →UPB▼ -6.1%on this news· ran to -18% by day 3shared move
Upstream Bio Announces Addition to Russell 2000 Index
Upstream Bio, Inc. has announced its inclusion in the Russell 2000 index, effective December 23, 2024. This recognition follows the company's focus on developing treatments for inflammatory diseases, particularly severe respiratory disorders, and highlights their candidate, verekitug. The inclusion could enhance the company's visibility among investors. However, Upstream Bio faces challenges related to regulatory approvals and funding for its ongoing clinical trials and product development.
Read more →UPBUpstream Bioprocessing Market to Reach USD 82.10 Billion by 2032 from USD 22.79 Billion in 2023 | CAGR of 15.35%
The upstream bioprocessing market is set to expand from USD 22.79 billion in 2023 to USD 82.10 billion by 2032, growing at a CAGR of 15.35%. This growth is driven by increasing demand for biopharmaceuticals and significant advancements in bioprocessing technology. Innovations such as single-use bioreactors and automation are optimizing production processes, while the Asia Pacific region is anticipated to see rapid market growth due to heightened investment and healthcare needs. The report highlights key players and trends shaping the market dynamics.
Read more →UPBUpstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio, Inc. will have its CEO, Rand Sutherland, participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024. The conference will showcase the company’s development of verekitug, an innovative monoclonal antibody targeting inflammatory diseases, particularly severe respiratory disorders. A live webcast of the presentation will be available, and a replay will be accessible for 90 days. The company aims to address significant unmet medical needs in this area.
Read more →UPBUpstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights – Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – – Commenced start
Upstream Bio reported its financial results for Q3 2024, highlighting advances in clinical trials for its monoclonal antibody, verekitug, targeting severe asthma and CRSwNP. The company raised approximately $293 million through its upsized IPO, providing financial stability through 2027. Promising preliminary data shows verekitug's potential potency in asthma treatments, with expectations for further results in upcoming Phase 2 trials. However, the company faces challenges with rising operational costs and recent net losses.
Read more →UPBUpstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Upstream Bio, Inc. announced the successful closure of its $293 million upsized initial public offering, which involved 17,250,000 shares at $17.00 each. The offering includes 2,250,000 shares from the underwriters' exercise of their option to purchase additional shares. Trading on the Nasdaq under the symbol 'UPB' commenced on October 11, 2024. Upstream Bio is focused on developing innovative treatments for inflammatory diseases, particularly targeting severe respiratory disorders with its monoclonal antibody, verekitug.
Read more →UPBUpstream Bio Announces Pricing of Upsized Initial Public Offering
Upstream Bio, Inc. has announced the pricing of its upsized initial public offering of 15 million shares at $17.00 each, set to start trading on Nasdaq with the ticker UPB on October 11, 2024. The IPO is projected to generate gross proceeds of $255 million, which will provide significant funding for the company's projects focused on severe respiratory disorders. Additionally, the company has drawn attention with its development of verekitug, a monoclonal antibody targeting inflammatory diseases. The IPO offering is expected to close on October 15, 2024.
Read more →UPBUpstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress
Upstream Bio, Inc. announced promising data regarding its investigational drug verekitug (UPB-101) at the European Respiratory Society Congress 2024. The findings from a Phase 1b trial indicate that verekitug led to significant reductions in asthma-related inflammatory biomarkers, with rapid and sustained effects observed over 24 weeks. Predictive pharmacokinetic modeling suggests that dosing regimens every 12 or 24 weeks could maintain effective drug levels, supporting the ongoing Phase 2 VALIANT clinical trial. The results position verekitug as a differentiated candidate in asthma treatment.
Read more →UPBUpstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
Upstream Bio presented promising results from a dose-ranging study of verekitug (UPB-101) at the American Thoracic Society's conference. The study highlighted a significant 54% reduction in fractional exhaled nitric oxide (FENO) levels in asthma patients, sustained for up to 24 weeks after treatment. Verekitug demonstrated favorable safety and tolerability, with no clinically meaningful immunogenicity. The findings suggest potential for effective treatment intervals and support ongoing Phase 2 trials in severe asthma and chronic rhinosinusitis with nasal polyps.
Read more →UPBUpstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference
Upstream Bio, Inc. will present clinical data on verekitug (UPB-101), a novel TSLP receptor antagonist, at the American Thoracic Society International Conference. The presentation is scheduled for May 22, 2024, and will focus on results from a dose-ranging study in adults with asthma. Verekitug has previously shown promise in multiple clinical trials, demonstrating safety and potential effectiveness for severe asthma and other inflammatory diseases.
Read more →UPBUpstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients
Upstream Bio has initiated the Phase 2 VALIANT clinical trial for verekitug (UPB-101) in severe asthma patients, following positive results from earlier studies. The trial will assess the efficacy of various dosing regimens of verekitug, a monoclonal antibody targeting TSLP signaling. The company aims to demonstrate significant clinical outcomes that could benefit asthma patients.
Read more →UPBUpstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Upstream Bio has initiated dosing for the first patients in a Phase 2 clinical trial of verekitug, targeting chronic rhinosinusitis with nasal polyps (CRSwNP). This trial is notable as it is the first multi-national study utilizing a TSLP pathway inhibitor with a dosing interval of every 12 weeks. The trial aims to evaluate the efficacy of verekitug in reducing nasal polyp scores, building on promising Phase 1b results in asthma patients.
Read more →UPBBioSpace: Upstream Bio’s Quest for Effective Best-in-Class Treatments for Allergic Inflammation
Upstream Bio is advancing UPB-101, a monoclonal antibody targeting TSLP, to treat severe asthma. Recent Phase 1b data shows significant reduction in biomarkers, indicating potential best-in-class efficacy. The company plans to move into Phase 2 trials with extended dosing intervals, aiming to improve treatment accessibility for patients with both Type 2 and non-Type 2 asthma.
Read more →UPBUpstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2
Upstream Bio announced positive interim results for UPB-101 in its Phase 1b clinical trial for asthma, indicating strong safety and tolerability. The results support advancing to Phase 2, with potential dosing regimens at 12 and 24-week intervals. The trial showed full receptor saturation and significant biomarker suppression, paving the way for further studies.
Read more →Competitive Position
How UPB ranks across every disease it competes inCompetitive Position is a premium feature
See how UPB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial